The Catalan biotechnology company AB-Therapeutics, that focuses on drug development, has just hired José Alfón as Director of Development. Alfón previously served as Drug Development Project Leader at Palau Pharma.

In bringing Alfón aboard, AB-Therapeutics has finished putting together a solid team of scientists with broad international experience. His mission will be to direct the company’s recently begun preclinical development program for an anti-cancer drug candidate through the clinical phase.

José Alfón, 43, earned a Bachelor of Pharmacy and an MS in Pharmaceutical Sciences from the Hebrew University of Jerusalem, and a PhD in Pharmaceutical Sciences from the University of Barcelona (UB). He has over ten years experience in identifying drug candidates and in developing drugs from the discovery stage to Phase II clinical trials. In addition to Palau Pharma, where has spent most of his career to date, he has also held various research positions at the Hebrew University of Jerusalem, the Spanish National Research Council (CSIC), and different hospitals in the UK and Israel.

ABOUT AB-THERAPEUTICS

AB-Therapeutics, SL is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).

AB-Therapeutics, SL develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a molecule ready to start preclinical development in 4Q2010, with Phase I clinical trials (first in man) starting in late 2011 / early 2012. A second drug candidate will start preclinical development in 2Q2011.

Contact:
 
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com